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Introduction
Treatment with anti-TNF therapies (anti-TNF) for polyar-
ticular forms (extended oligo, Poly RF +/-) of JIA (PF-JIA)
results in >50% demonstrating clinical inactive disease
(CID).
Objectives
The aims of this study were to perform the first pro-
spective, mulicenter trial to determine the frequency,
timing and predictors of flare upon withdrawal of anti-
TNF in PF-JIA in CID.
Methods
In 16 centers 137 children with PF-JIA in CID on anti-
TNF were enrolled and prospectively followed. If CID
was maintained for the first 6 study mos, then anti-TNF
was stopped and the patients were followed prospectively
by protocol. Background meds were stable.
Results
The study population included 18 (13%) extended oligoar-
ticular, 17 (12%) RF+ Poly and 102 (75%) RF- Poly JIA
patients. At enrollment, age (mean/median/range) was
11.3/11.6/3.4-20.1 yrs; disease duration was 5.0/4.1/0.6-
18.6 yrs; 103 (75%) were females and 64 (47%) were ANA
+. Duration of CID at baseline was 1.2/0.5/1 day-12.1 yrs.
Anti-TNF was etanercept in 106 (77%), 25 (18%) adalimu-
mab and 6 (5%) infliximab. 40% were on MTX at baseline
(mean/median dose 0.4/0.4 mg/kg/wk).
17% were unable to maintain CID for the first 6 months
despite stable background medications. For the extended
oligo, Poly RF – and Poly RF+ categories 94%, 82% and
60%, respectively, maintained CID for the first 6 months
(chi-square 6.7, p 0.03). ANA status, MTX use, and type
of anti-TNF were not associated with the ability to main-
tain CID (chi-square p values 0.48, 0.14, and 0.75,
respectively).
Upon stopping the anti-TNF therapy, the mean time to
flare was 18.3 months with a median of 26 months (range
9-32 months). Longer disease duration at baseline was
associated with an increasing risk of flare with stopping
anti-TNF therapy (chi square 5.62, p = 0.017). Background
MTX significantly decreased the risk of flare (p= 0.05) and
significantly increased the time to flare (p = 0.05). JIA sub-
type was significantly associated with both risk of flaring
(p=0.02) and time to flare (p= 0.04) with RF+ Poly flaring
less frequently than either RF- or Extended oligo which
seem similar. RF+ patients were significantly less likely to
flare than RF- (p= 0.02). Age, gender, ANA status, dura-
tion of CID did not predict risk of or time to flare.
Conclusion
In these patients with Polyarticular forms of JIA in CID
for ≥6 mos, upon stopping the anti-TNF therapy, 70%
will experience a flare within 3.25 years but ≥ 50% will
maintain CID for ≥17 months. Continuing background
MTX both decreases the risk of flare and increases the
time to flare. Disease duration and JIA subtype are the
only predictive clinical parameters. Duration of CID was
NOT predictive of risk of flare after stopping anti-TNF
therapy.
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